Appendix 4C & Quarterly Update

• US FDA lifted the clinical hold on NUZ-001 Investigational New Drug (IND) application – a key regulatory inflection point and cleared the path for clinical development of NUZ-001 in the treatment of ALS • Subsequent FDA clearance granted for NUZ-001 to enter the HEALEY ALS Platform Trial, with NUZ-001 officially confirmed as Regimen I following completion of the FDA’s 30-day review of the protoc